Iovance Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| 0JDK.L | IMCR | 0A3M.IL | INCY | IDYA | AIM | |
|---|---|---|---|---|---|---|
| Market cap | — | 1.36B | 22.20B | 23.36B | 2.47B | 4.57M |
| P/E (TTM) | — | — | 4.5 | 58.5 | — | — |
| Forward P/E | — | -41.1 | 4.5 | 13.3 | -6.1 | -0.3 |
| Price/book | 3.9 | 3.2 | 1.0 | 4.1 | 2.3 | 0.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +228.13% | −32.33% | −16.71% | +13.53% | −23.01% | −90.97% |
| Today | −6.23% | −0.83% | −2.17% | −1.07% | −2.33% | −4.50% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0JDK.L news ›Iovance Biotherapeutics to Present at Upcoming Conference
PHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL)…
Barclays Remains a Buy on Iovance Biotherapeutics (IOVA)
Barclays analyst Etzer Darout maintained a Buy rating on Iovance Biotherapeutics today and set a price target of $19.00. According to TipRanks, Darout is a 5-star analyst with an average return of 23.8% and a 53.85% success rate. Darout…
More from 1 other outlet
Iovance Biotherapeutics (IOVA): The Growth Story Gathers Steam, But Can The Stock Turn The Tide?
FDA approval is undoubtedly a significant milestone, but it is only half the battle. The real test lies in translating regulatory success into physician adoption, patient demand and, ultimately, sustainable revenue growth. • Growing demand…
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Iovance Biotherapeutics (IOVA)
TipRanks Nov. 5, 2026, 02:00 PM There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (
Iovance Biotherapeutics (IOVA) – Analysts’ Weekly Ratings Changes
Posted by Danessa Lincoln on Nov 10th, 2026 Iovance Biotherapeutics (NASDAQ: IOVA) has recently received a number of price target changes and ratings updates: Iovance Biotherapeutics is a biotechnology company focused on developing and…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Nuvectis Pharma (NVCT) and Pfizer (PFE)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA), Nuvectis Pharma (NVCT) and Pfizer (PFE). H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Iovance…
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic Non-Small-Cell Lung Cancer (mNSCLC)…
Iovance Biotherapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-06. The following slide deck was published by Iovance Biotherapeutics, Inc. The following slide deck was published by Iovance Biotherapeutics, Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-11-05 Earnings Summary
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Target Raised at Citizens Jmp
Posted by Kim Johansen on Nov 6th, 2026 Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) had its target price increased by stock analysts at Citizens Jmp from $8.00 to $12.00 in a report issued on Friday, Benzinga reports. The…
Iovance Biotherapeutics shares drop 46% after valuation downgrade despite melanoma drug progress
Iovance Biotherapeutics' stock fell 46% following a downgrade to Hold due to over-optimism in its valuation. While the melanoma drug AMTAGVI (lifileucel) is gaining market traction, the potential for its use in non-small cell lung cancer…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com6
- markets.businessinsider.com3
- seekingalpha.com3
- theglobeandmail.com3
- globenewswire.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.